11/3/2026

speaker
Conference Operator
Operator

Hello, and welcome to Tarsus Pharmaceuticals' third quarter 2026 Financial Results Conference call. As a reminder, this call is being recorded, and all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.

speaker
David Nakasone
Head of Investor Relations

Thank you. Before we begin, I encourage everyone to visit the investor section of the Tarsus website to view the press release issued today and related materials we will be discussing today. Joining me on the call today are Bobby Azamian, Chief Executive Officer and Chairman, Neera Klase, our Chief Commercial Officer, Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. And joining us for Q&A is Dr. Liz You, our Chief Medical Officer, and Seshadri Neervannan, our Chief Operating Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I will turn the call over to Bobby.

speaker
Bobby Azamian
Chief Executive Officer and Chairman

Good afternoon, and thank you for joining us. One million, one billion, five and five. More than one million bottles of Xtemvi dispensed, more than one billion dollars in cumulative next product sales, and a pipeline with the potential to bring five new medicines to patients in the next five years. As we celebrate our 10th anniversary, those numbers say a lot about how far Tarsus has come. but what excites me the most is what they tell us about where we can go. We started with a conviction that there were important diseases in eye care hiding in plain sight and that following the science to their root cause could lead to entirely new categories of medicine. Extenvi showed what that conviction could accomplish. This quarter, we delivered record sales and are again raising our full year outlook. Neera and Jeff will take you through the details and why we believe Xtempi is just getting started. I want to talk about our broader ambition, building the next leader in eye care. Not one defined by a single drug, but by a repeatable ability to spot a disease the field has overlooked, bring forward a medicine that could change how it's treated, and bring it to patients. That's the standard we're applying across our pipeline. We want to be first or best, and we're choosing opportunities where we believe we can make a meaningful difference. With Stargardt disease, that means the potential to help children and young adults preserve vision they would otherwise lose. With IRX101, it means improving antiseptic preparation for patients receiving repeated retinal injections. And with our existing investigational programs for ocularization and Lyme disease prevention, We have opportunities to address other diseases where patients still need better answers. Together, they give us what we believe is one of the most differentiated pipelines in eye care. Three years ago, we were launching a single product for a disease most people had never heard of. Today, we're a team that built the category from scratch, closed two acquisitions in two months, and is running several clinical programs. There was no playbook for any of it, So we wrote one.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation